



AGENDA

Life Science Event 2026 – From molecule to market October 1, 2026

TIME	TOPIC
1:30 pm	Get together
2:00 pm	Introduction and Welcome <i>Andrew Whytock, Siemens</i>
	Reinventing Biopharma: From Lab to Line <i>Andrew Alderman, Accenture</i>
	From Molecule to Market: Connecting the Digital Threads with AI <i>Andrew Whytock, Siemens</i>
	Platform processes for antibodies and ATMPs to accelerate downstream processing development <i>Prof. Alois Jungbauer, BOKU University</i>
	Break
	From Molecule to Pathway: How SYNTHIA® + Luma Connects Retrosynthesis to the Lab <i>Christopher Rundell, Dotmatics; Ewa Gajewska, Merck Group</i>
	Smart Lab of the Future <i>Thomas Riffel, Siobhan Fleming, Siemens</i>
	From Digital Labs to Autonomous Labs: The Next Frontier of Scientific Operations <i>Mark Lugenbühl, Accenture</i>
	Break
	Engineering Excellence integrated Tech Transfer: AI-Augmented Tech Transfer for faster time-to-market <i>Veronika Nindl, Mathias Zelenka, VTU</i>
	Next level of Process automation <i>Franz Winkler, Takeda</i>
	From Legacy to Live Insight <i>Christoph Lex, Alexander Rieger, Fresenius Kabi</i>
	Closing <i>Andrew Whytock, Siemens</i>
6:30 pm	Lab Tour and Networking Dinner

ABSTRACTS

Life Science Event 2026 – From molecule to market October 1, 2026



Reinventing Biopharma: From Lab to Line

As AI accelerates innovation and new therapies increase in complexity, translating laboratory breakthroughs into commercial manufacturing is becoming a critical challenge for the life sciences industry. Drawing on recent industry research and practical experience, we will explore why organisations need a Digital CMC foundation to connect development and manufacturing, improve technology transfer, strengthen process knowledge and accelerate the journey from laboratory innovation to commercial production. Attendees will gain insights into how digital capabilities can improve speed, quality, and scalability across the product lifecycle.

Andrew Alderman, Accenture

From Molecule to Market: Connecting the Digital Threads with AI

Bringing therapies to patients faster requires seamless collaboration across research, process development, manufacturing and supply chain operations. This session explores how digital threads, industrial AI and connected lifecycle data can create a true molecule-to-market approach, enabling faster decisions, greater agility and more efficient operations across the biopharma value chain.

Andrew Whytock, Siemens

Platform processes for antibodies and ATMPs to accelerate downstream processing development

Can platforms really be transferred from one molecule to another, despite the success story of antibody purification platforms? The diversity of biophysical properties in surface characteristics, size, conformational stability, and others – makes extrapolation difficult, also due to a lack of data; therefore, help of AI is currently limited. Examples of unit operations that have proven to be robust platforms will be presented.

Prof. Alois Jungbauer, BOKU University

From Molecule to Pathway: How SYNTHIA® + Luma Connects Retrosynthesis to the Lab

For many chemistry teams, generating synthetic routes isn't the hard part. The challenge lies in what follows, namely, route reviews spread across disconnected tools, time lost rebuilding context with every switch, and decisions that are hard to document and act upon consistently. Meanwhile, valuable experimental data often sits disconnected from the route planning process itself. This talk walks through an example workflow that addresses these challenges directly. A target molecule moves from ranked retrosynthetic pathways generated in SYNTHIA®, to an AI-assisted drafted protocol, to a ready-to-run ELN experiment, all within the Luma ecosystem. Along the way, we'll show how bringing structured experimental data into the route evaluation process helps chemists make decisions with more confidence, without needing to switch tools or lose context along the way.

Christopher Rundell, Dotmatics; Ewa Gajewska, Merck Group

Smart Lab of the Future

Modern, flexible, customer centric laboratories start with a lab design simulation. This leads to smart laboratory design delivering all important data for the laboratory operations control. This data combined with the experiments, further simulations supporting the customer in their digital drug discovery and development.

Thomas Riffel, Siobhan Fleming, Siemens

From Digital Labs to Autonomous Labs: The Next Frontier of Scientific Operations

Laboratories are facing a new era of operational transformation. Rising complexity, talent shortages and increasing pressure to accelerate scientific outcomes are driving the need for smarter operating models. This session explores how autonomous robotics, Physical AI, and digital twins are converging to create intelligent, self-optimizing laboratory operations. We will demonstrate how organizations can accelerate innovation, increase productivity and scale operations through autonomous laboratory ecosystems.

Mark Lugenbühl, Accenture

Engineering Excellence integrated Tech Transfer: AI-Augmented Tech Transfer for faster time-to-market

AI and digital technologies are compressing early R&D timelines, but the transition from development to manufacturing remains a critical bottleneck. This presentation discusses how AI-augmented Process Engineering and MSAT can support faster tech transfer through structured knowledge capture, early scale-up assessment and digital engineering workflows. The focus is on integrating engineering excellence early into tech transfer to reduce rework, increase knowledge sharing and traceability and shorten time-to-market.

Veronika Nindl, Mathias Zelenka, VTU

Next level of Process automation

Discover how standardization, simulation, and digital twins are already shaping pharma automation today. This session takes a practical look at how these solutions can improve engineering, operations, and collaboration. It also offers a technical perspective on the future of pharma automation.

Franz Winkler, Takeda

From Legacy to Live Insight

Fresenius Kabi Austria's Automation & OT team shares how it replaced an ageing legacy historian with MACS, a Siemens WinCC OA-based SCADA system spanning two GMP manufacturing sites. The session covers how structured trending and alarm management turned manual documentation into fast, traceable processes – and looks ahead to a shared vision for a centralized, cross-vendor audit trail.

Christoph Lex, Alexander Rieger, Fresenius Kabi